MX2020001732A - Tratamiento de las afecciones del sistema nervioso central. - Google Patents
Tratamiento de las afecciones del sistema nervioso central.Info
- Publication number
- MX2020001732A MX2020001732A MX2020001732A MX2020001732A MX2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A MX 2020001732 A MX2020001732 A MX 2020001732A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- treatment
- nervous system
- central nervous
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553070P | 2017-08-31 | 2017-08-31 | |
| PCT/JP2018/032949 WO2019045121A1 (en) | 2017-08-31 | 2018-08-30 | TREATMENT OF CNS DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001732A true MX2020001732A (es) | 2020-03-20 |
Family
ID=63722720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001732A MX2020001732A (es) | 2017-08-31 | 2018-08-30 | Tratamiento de las afecciones del sistema nervioso central. |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11285139B2 (https=) |
| EP (1) | EP3675852A1 (https=) |
| JP (2) | JP7196157B2 (https=) |
| KR (1) | KR102680786B1 (https=) |
| CN (2) | CN116370475A (https=) |
| CA (1) | CA3073925A1 (https=) |
| MX (1) | MX2020001732A (https=) |
| WO (1) | WO2019045121A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119192266A (zh) | 2011-10-14 | 2024-12-27 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| ES2807264T3 (es) | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015010054A2 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2848823T3 (es) | 2013-08-23 | 2021-08-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016123056A1 (en) | 2015-01-26 | 2016-08-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| PT3711758T (pt) | 2017-11-14 | 2024-04-22 | Sk Biopharmaceuticals Co Ltd | Utilização de composto de carbamato para prevenir, aliviar ou tratar crise de ausência ou epilepsia que apresenta crise de ausência |
| WO2020021372A1 (en) * | 2018-07-24 | 2020-01-30 | Zenvision Pharma Llp | Nasal drug delivery system of brivaracetam or salt thereof thereof |
| GB2580881A (en) * | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| JP2023504177A (ja) * | 2019-12-02 | 2023-02-01 | エフ．ホフマン－ラ ロシュ アーゲー | アルキニル－（ヘテロアリール）－カルボキサミドｈｃｎ１阻害剤 |
| GB2597285A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597312A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597311A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| US20240197704A1 (en) * | 2021-04-09 | 2024-06-20 | Johns Hopkins University | Treatment methods and compositions comprising perampanel |
| CN115487144A (zh) * | 2021-06-18 | 2022-12-20 | 北京万全德众医药生物技术有限公司 | 一种卢非酰胺的口服液制备方法 |
| WO2023175591A1 (en) * | 2022-03-18 | 2023-09-21 | Takeda Pharmaceutical Company Limited | Methods of treating neurological diseases |
| WO2024100531A1 (en) * | 2022-11-07 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Method of treating seizure disorders |
| WO2025126159A1 (en) * | 2023-12-15 | 2025-06-19 | Takeda Pharmaceutical Company Limited | A method for treating a neurological disease in a recreational drug user |
| WO2025257799A1 (en) * | 2024-06-14 | 2025-12-18 | Takeda Pharmaceutical Company Limited | Methods of treating dravet syndrome |
| CN121550436A (zh) * | 2026-01-23 | 2026-02-24 | 四川大学华西医院 | 新靶点在结节性硬化症相关癫痫中的应用、组合物及联合用药方式 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2763979T3 (pl) | 2011-10-07 | 2019-06-28 | Takeda Pharmaceutical Company Limited | Związki 1-arylokarbonyl-4-oksy-piperydynowe użyteczne do leczenia chorób neurodegeneracyjnych |
| PE20151162A1 (es) | 2012-12-11 | 2015-08-28 | Takeda Pharmaceutical | Compuestos heterociclicos inhibidores del colesterol 24-hidroxilasa (ch24h) |
| JP6272832B2 (ja) | 2013-04-04 | 2018-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6807322B2 (ja) | 2015-10-16 | 2021-01-06 | 武田薬品工業株式会社 | 複素環化合物の製造方法 |
-
2018
- 2018-08-30 WO PCT/JP2018/032949 patent/WO2019045121A1/en not_active Ceased
- 2018-08-30 KR KR1020207004753A patent/KR102680786B1/ko active Active
- 2018-08-30 US US16/642,153 patent/US11285139B2/en active Active
- 2018-08-30 CN CN202310328785.4A patent/CN116370475A/zh active Pending
- 2018-08-30 MX MX2020001732A patent/MX2020001732A/es unknown
- 2018-08-30 CA CA3073925A patent/CA3073925A1/en active Pending
- 2018-08-30 CN CN201880055307.8A patent/CN111065394B/zh active Active
- 2018-08-30 EP EP18782213.5A patent/EP3675852A1/en active Pending
- 2018-08-30 JP JP2020511399A patent/JP7196157B2/ja active Active
-
2022
- 2022-02-16 US US17/673,072 patent/US20220168294A1/en not_active Abandoned
- 2022-08-23 US US17/893,905 patent/US20230087903A1/en not_active Abandoned
- 2022-12-14 JP JP2022199076A patent/JP7469445B2/ja active Active
-
2024
- 2024-09-13 US US18/885,342 patent/US20250281477A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020532508A (ja) | 2020-11-12 |
| CN111065394B (zh) | 2023-03-31 |
| EP3675852A1 (en) | 2020-07-08 |
| JP7469445B2 (ja) | 2024-04-16 |
| JP2023027267A (ja) | 2023-03-01 |
| CN116370475A (zh) | 2023-07-04 |
| US20220168294A1 (en) | 2022-06-02 |
| CA3073925A1 (en) | 2019-03-07 |
| US20250281477A1 (en) | 2025-09-11 |
| US20230087903A1 (en) | 2023-03-23 |
| US11285139B2 (en) | 2022-03-29 |
| CN111065394A (zh) | 2020-04-24 |
| JP7196157B2 (ja) | 2022-12-26 |
| WO2019045121A1 (en) | 2019-03-07 |
| US20200306238A1 (en) | 2020-10-01 |
| KR102680786B1 (ko) | 2024-07-02 |
| KR20200046022A (ko) | 2020-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| CL2023000095A1 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CO2019001625A2 (es) | Compuestos de captura de aldehído y usos de los mismos | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| EA201892216A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| MX389545B (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| MX2018003023A (es) | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| MX2016010085A (es) | Metodos para tratar lesion del cerebro leve. | |
| ES3060711T3 (en) | 3-hydroxy-5-pregnane-20-one derivative and use thereof | |
| CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina | |
| CL2021000743A1 (es) | Métodos para tratar trastornos mieloproliferativos | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| MX2018001684A (es) | Metodo de curacion de heridas. |